Literature DB >> 35501818

Myasthenia gravis coexisting with HINT1-related motor axonal neuropathy without neuromyotonia: a case report.

Jia Fang1, Hui Huang2, Qiang Lei1, Yingying Luo1, Zhengchu Tang1, Xiaoliu Shi2, Jian Guang Tang3.   

Abstract

BACKGROUND: HINT1 mutations cause an autosomal recessive axonal neuropathy with neuromyotonia. This is a first case report of coexistence of myasthenia gravis (MG) and HINT1-related motor axonal neuropathy without neuromyotonia. CASE
PRESENTATION: A 32-year-old woman presented with recurrent ptosis for 8 years, diplopia for 2 years and limb weakness for 1 year and a half. Neostigmine test, elevated AChR antibody level and positive repetitive nerve stimulation supported the diagnosis of MG. Electroneurography (ENG) and electromyography (EMG) examinations revealed a motor axonal neuropathy without neuromyotonic or myokymic discharges. Next-generation sequencing and Sanger sequencing were performed to identify the gene responsible for suspected hereditary neuropathy. Genetic testing for a HINT1 mutation was performed and revealed a homozygous mutation at c.278G>T (p. G93V). The patient was treated with pyridostigmine, oral prednisolone and azathioprine. Her ptosis and diplopia have significantly improved at 6-month follow-up.
CONCLUSIONS: Concurrence of MG and hereditary motor axonal neuropathy without neuromyotonia is quite rare. Detection of ptosis with or without ophthalmoplegia, distribution of limb weakness, and reflex can help in recognizing the combination of MG and peripheral neuropathy. Early diagnosis is important for initial treatment and prognosis. The novel homozygous variant c.278G>T(p.G93V) contributes to the pathogenic variants spectrum of the HINT1 gene.
© 2022. The Author(s).

Entities:  

Keywords:  Case report; HINT1; Motor axonal neuropathy; Myasthenia gravis; Next-generation sequencing; Novel

Mesh:

Substances:

Year:  2022        PMID: 35501818      PMCID: PMC9063049          DOI: 10.1186/s12883-022-02690-6

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


Background

Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission [1]. MG is clinically characterized by fluctuating muscle weakness with oculobulbar muscles affected earlier and more frequently than other muscles [1]. Muscle weakness usually shows dramatic improvement on cholinesterase inhibitors. Electrophysiological studies are characterized by decrement in compound muscle action potential (CMAP) amplitude in response to low-frequency repetitive nerve stimulation (RNS). In 2012, pathogenic mutations in the gene encoding the histidine triad nucleotide binding protein 1 (HINT1) were identified by Zimoń et al. in autosomal recessive motor predominant axonal neuropathy with neuromyotonia [2]. HINT1 mutations may account for 11% of all inherited neuropathies with autosomal recessive inheritance and for 80% of individuals with axonal neuropathy having the clinical hallmark of neuromyotonia. HINT1 neuropathy has a worldwide distribution and is particularly prevalent in European countries [3]. Recently it has been reported in Chinese population [4, 5]. In the present study, we reported the first case of ocular MG, whose diagnosis was challenged by the coexistence of HINT1-related hereditary axonal neuropathy without clinical or electrophysiological features of neuromyotonia.

Case presentation

A 32-year-old female was admitted to hospital due to recurrent bilateral ptosis for 8 years, diplopia for 2 years and limb weakness for 1 year and a half. Eight years ago, she developed ptosis. After taking mecobalamin orally for a few months, her symptoms completely recovered. Two years ago, ptosis recurred along with diplopia, and half a year later, her condition was aggravated by limb weakness with the distal muscles more severely affected than the proximal muscles. Since then, she couldn’t take care of herself independently, and couldn’t walk on a level road without support. Fluctuations in muscle strength were not pronounced. She had normal motor development milestones but began to notice poor performance in sports since school age, and during her adult life. She can only do some indoor housework, but not the outdoor heavy farm work. During the course of the disease, no neurodevelopmental abnormalities or psychiatric symptoms were observed. The patient was born from consanguineous parents, and she has a negative family history of neurological or neuromuscular disease. Her physical examination on admission revealed bilateral ptosis, complete external ophthalmoplegia, and diplopia. Muscle strength was 2/5 for finger/wrist extension and ankle dorsiflexion/plantar flexion, 3/5 for wrist/finger bending, while proximal muscle strength was 4/5 for upper limbs and lower limbs (grades 0–5 on the Medical Research Council Scale). The tendon reflex of both upper limbs was normal and symmetrical. The knee reflex and Achilles tendon reflex were absent, and the plantar reflexes were flexor. There were atrophy of the distal muscles of upper and lower limbs, per cavus, claw-like hands, and a steppage gait. Sensory examinations were normal. No signs of neuromyotonia were observed. Intramuscular injection of neostigmine 1 mg significantly improved her ptosis and diplopia. The acetylcholine receptor (AChR) antibody was elevated (11.793 nmol/L, normal < 0.5 nmol/L). Immunofixation electrophoresis in blood and urine was normal. Thyroid function was normal. Computed tomography of the chest showed no parenchymal abnormalities. The result of lumbar puncture cerebrospinal fluid examination was normal. Brain and spine MRI were not done, since there were no neuropsychiatric symptoms. Electromyographic studies revealed a chronic motor axonal neuropathy, without neuromyotonic or myokymic discharges (Table 1). Electromyography (EMG) showed complex repetitive discharges (CRD) in the right biceps brachii, left quadriceps femoris, left anterior tibialis muscle, T12 paraspinal muscle. Decremental CMAP responses in low frequency RNS were recorded in the right deltoid muscle and the left trapezius muscle, and were not observed in the left deltoid muscle, left abductor digiti minimi muscle, right abductor pollicis brevis, and right trapezius. The magnitude of decrement was 27.4% in the right deltoid muscle and 17.7% in the left trapezius muscle respectively. The diagnosis of MG was established, and a concomitant hereditary motor axonal neuropathy was also suspected. Next generation sequencing (NGS) identified a novel homozygous missense variant c.278G > T (p.G93V) in the patient, which was later confirmed by Sanger sequencing. Her parents and the healthy younger brother all were heterozygous carriers (Fig. 1). The amino acid G93 in HINT1 is highly evolutionarily conserved among different species [2]. The variant c.278G > T (p.G93V) was neither found in 1000 Genomes Project databases nor in Exome Aggregation Consortium databases. Several online softwares including MutationTaster, SIFT and polyphen2 predicted that the variant may have a deleterious effect on the gene product. A different amino acid substitution for Glycine (Gly, G) at position 93 of the HINT1 protein occurred in a patient with autosomal recessive axonal neuropathy with neuromyotonia [2]. According to the ACMG guidelines, the variant c.278G > T (p.G93V) in HINT1 can be classified as likely pathogenic. Consequently, the diagnosis of HINT1-related hereditary axonal motor neuropathy was considered.
Table 1

Nerve conduction study data showing a predominantly axonal motor neuropathy

LatencyAmplitudeNCV
Motor NCS
Median nerve (left)
 APB, Wrist4.62 ms2.6 mV
 Wrist, Elbow8.79 ms2.1 mV57.6 m/s
Median nerve (right)
 APB, Wrist4.12 ms2.6 mV
 Wrist, Elbow8.29 ms2.4 mV51.6 m/s
Ulnar nerve (left)
 ADM, Wrist4.06 ms0.75 mV
 Wrist, below elbow8.42 ms0.68 mV48.2 m/s
Ulnar nerve (right)
 ADM, Wrist3.25 ms1.91 mV
 Wrist, below elbow7.25 ms1.64 mV53.8 m/s
Tibial nerve (left)
 AH, ankle5.74 ms1.84 mV
 Ankle, Pop fossa13.9 ms1.14 mV42.9 m/s
Tibial nerve (right)
 AH, ankle6.87 ms0.71 mV
 Ankle, Pop fossa14.4 ms0.33 mV45.8 m/s
Fibular nerve (left)
 EDB, ankleNR
 Fibular headNR
Fibular nerve (right)
 EDB, ankle8.19 ms0.042 mV
 Fibular head15.7 ms0.040 mV39.9 m/s
Sensory NCS
Median nerve (left)2.25 ms37.7 μV60.0 m/s
Median nerve (right)2.48 ms37.9 μV58.5 m/s
Ulnar nerve (left)2.04 ms26.6 μV56.4 m/s
Ulnar nerve (right)2.18 ms26.7 μV50.5 m/s
Peroneal nerve (left)2.54 ms7.2 μV49.2 m/s
Peroneal nerve (right)2.13 ms10.7 μV51.6 m/s
Sural nerve (left)2.13 ms11.0 μV46.9 m/s
Sural nerve (right)1.78 ms11.0 μV53.4 m/s

Values shown in bold are abnormal

NCV nerve conduction velocity, APB abductor pollicis brevis, ADM abductor digiti minimi, AH abductor hallucis, EDB extensor digitorum brevis, NR not recordable, NCS nerve conduction studies, NCV nerve conduction velocity, Pop fossa popliteal fossa

Fig. 1

A homozygous mutation of the c.278G > T(p.G93V) of the HINT1 gene was identified in the proband and marked with arrow. The same heterozygous variant was found in the patient’s father, mother, and brother

Nerve conduction study data showing a predominantly axonal motor neuropathy Values shown in bold are abnormal NCV nerve conduction velocity, APB abductor pollicis brevis, ADM abductor digiti minimi, AH abductor hallucis, EDB extensor digitorum brevis, NR not recordable, NCS nerve conduction studies, NCV nerve conduction velocity, Pop fossa popliteal fossa A homozygous mutation of the c.278G > T(p.G93V) of the HINT1 gene was identified in the proband and marked with arrow. The same heterozygous variant was found in the patient’s father, mother, and brother The patient received a therapy with pyridostigmine (60 mg/6 h), oral prednisolone (35 mg/24 h) and azathioprine (100 mg/24 h). After 6 months of therapy, ptosis and diplopia greatly improved with only mild adduction deficit of the right eye. Unfortunately there has been little recovery in limb weakness. The dose of prednisone was reduced to 30 mg/24 h. Anti-AChR antibody remained elevated but to a lesser degree compared with the initial titer. She is currently followed up every 3–6 months in our neurology clinic.

Discussion and conclusions

This is the first report of ocular MG concurrent with HINT1-related hereditary motor axonal neuropathy. The clinical hallmark of MG consists of fluctuating fatigability and skeletal muscle weakness [1, 2]. Extraocular involvement (diplopia and/or ptosis) is generally the first clinical sign in MG, and in 15% of cases, symptoms and signs are confined to extraocular muscles [1]. The diagnosis of MG may become challenging for patients with neurological comorbidities or for those who present with atypical symptoms such as non-fluctuating weakness [6]. MG has been reported to associate with other autoimmune neurological diseases such as neuromyelitis optica spectrum disorders, multiple sclerosis, and Guillain Barre syndrome, etc. Rare cases of concurrence of MG and other neurological diseases have been reported, such as Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis [7-9]. Although the diurnal fluctuation of symptoms was not obvious in our patient, diplopia and recurrent ptosis supported a diagnosis of MG, which was confirmed later by auxillary examinations and response to immunotherapy. In our patient, MG can only account for ptosis and diplopia, while the distal muscle weakness and atrophy, as well as the absence of lower limb tendon reflexes indicated clearly an axonal motor neuropathy. As expected, electroneurography (ENG) confirmed a motor axonal neuropathy. The long history of poor performance in physical activities since her school age and her parental consanguinity provided clues to a possible hereditary disorder. HINT1-related hereditary motor axonal neuropathy was confirmed by genetic diagnosis eventually. The recessive mutations in HINT1 lead to a hereditary motor axonal neuropathy with disease onset typically within the first decade [2, 10]. Most patients present with distal limb muscle weakness and neuromyotonia [3]. Neuromyotonia is absent in around 20–30% of patients [11], making it difficult to diagnose some patients based solely on clinical and electrophysiological features. In some patients with HINT1-related neuropathy, subtle sensory involvement may develop later [12]. Some rare symptoms have been reported, such as pain in hands and lower extremities, speech difficulties and social behavioral alterations [13, 14]. The progression of the disease is very slow, and most of the reported patients remain ambulant until the sixth decade of life [4]. There is no curative treatment for HINT1-related neuropathy, therefore regular physical therapy, ankle-foot orthoses and special shoes remain mandatory. In our patient, the diagnosis of HINT1-related hereditary neuropathy was supported by the clinical and electrophysiological signs of chronic motor axonal neuropathy, the patient’s parental consanguinity, the homozygous mutation (p. G93V) of HINT1 identified in the patient but the corresponding heterozygous mutation in her healthy parents and brother, and at last, the likely pathogenicity of the homozygous mutation predicted by several softwares in silico. Neither neuromyotonia or myokymic discharges were shown on the initial EMG. After the genetic diagnosis, EMG was repeated and no signs of neuromyotonia were observed, which exemplified the difficulty in accurate diagnosis for some hereditary neuropathy with high clinical and genetic heterogeneity. One can rely on NGS to identify the responsible gene when encountering the diagnosis of atypical hereditary disorders, as is the case in our patient. HINT1 is a member of the histidine triad protein family, sharing a characteristic HIF motif (His-x-Hisx-x, where x is a hydrophobic residue) in the catalytic pocket [3]. The endogenous substrates of HINT1 remain unknown. HINT1 is highly expressed in brain and spinal cord, indicating its important role in the nervous system [15]. Functional studies showed the pathogenic HINT1 mutations responsible for a motor axonal neuropathy were loss of function. However, HINT1 knockout mice did not show any signs of neuropathy or neuromyotonia [16]. Hence, the mechanism underlying the pathogenesis of HINT1-related neuropathy remains to be elucidated. The coexistence of MG and HINT1-related neuropathy in our patient may not be coincidental. It’s reported that HINT1 exerts an immunoregulatory function in autoimmune diseases. HINT1 peptide/Hsp70 complex plays protective effects upon the development of experimental autoimmune encephalomyelitis [17]. It is reasonable to hypothesize that loss-of-function mutation in HINT1 may play a role in the pathogenesis of the autoimmune disease MG, but further studies are required. In conclusion, this is the first description of ocular MG coexistent with HINT1-related hereditary axonal neuropathy without clinical or electrophysiological features of neuromyotonia. Detection of ptosis with or without ophthalmoplegia, distribution of limb weakness, and reflex can help in recognizing concurrent MG and peripheral neuropathy. Early diagnosis has therapeutic and prognostic implications. Our results demonstrate the diagnostic value of NGS for the diagnosis of hereditary peripheral neuropathies. The case report broadens genotypic spectrum of HINT1-related neuropathy due to a novel homozygous variant c.278G>T (p. G93V) in HINT1. Further research is needed to fully elucidate the pathogenesis of the coexistence of MG and HINT1-related neuropathy.
  17 in total

Review 1.  Myasthenia Gravis.

Authors:  Nils E Gilhus
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

2.  A case of neuromyotonia and axonal motor neuropathy: A report of a HINT1 mutation in the United States.

Authors:  Nivedita U Jerath; Michael E Shy; Tiffany Grider; Ludwig Gutmann
Journal:  Muscle Nerve       Date:  2015-12       Impact factor: 3.217

3.  Novel mutations in HINT1 gene cause the autosomal recessive axonal neuropathy with neuromyotonia.

Authors:  Zhangyang Wang; Jie Lin; Kai Qiao; Shuang Cai; Victor W Zhang; Chongbo Zhao; Jiahong Lu
Journal:  Eur J Med Genet       Date:  2018-07-11       Impact factor: 2.708

4.  Novel mutations in HINT1 gene cause autosomal recessive axonal neuropathy with neuromyotonia in two cases of sensorimotor neuropathy and one case of motor neuropathy.

Authors:  Lingchao Meng; Jun Fu; He Lv; Wei Zhang; Zhaoxia Wang; Yun Yuan
Journal:  Neuromuscul Disord       Date:  2018-05-15       Impact factor: 4.296

5.  Lack of neuropathy-related phenotypes in hint1 knockout mice.

Authors:  Kevin L Seburn; Kathryn H Morelli; Albena Jordanova; Robert W Burgess
Journal:  J Neuropathol Exp Neurol       Date:  2014-07       Impact factor: 3.685

6.  Myasthenia gravis complicating Charcot-Marie-Tooth disease: report of a case.

Authors:  J R Berger; D R Ayyar; I Kimura; A Kovacs
Journal:  J Clin Neuroophthalmol       Date:  1985-06

7.  Coexistence of myasthenia gravis and amyotrophic lateral sclerosis in a Bosnian male: an unusual clinical presentation.

Authors:  Renata Hodzic; Nermina Piric; Sanela Zukic; Amela Cickusic
Journal:  Acta Myol       Date:  2021-03-31

Review 8.  Axonal neuropathy with neuromyotonia: there is a HINT.

Authors:  Kristien Peeters; Teodora Chamova; Ivailo Tournev; Albena Jordanova
Journal:  Brain       Date:  2017-04-01       Impact factor: 13.501

9.  HINT1 neuropathy in Norway: clinical, genetic and functional profiling.

Authors:  Silvia Amor-Barris; Helle Høyer; Albena Jordanova; Geir J Braathen; Kristien Peeters; Lin V Brauteset; Els De Vriendt; Linda Strand
Journal:  Orphanet J Rare Dis       Date:  2021-03-04       Impact factor: 4.123

10.  Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia.

Authors:  Magdalena Zimoń; Jonathan Baets; Leonardo Almeida-Souza; Els De Vriendt; Jelena Nikodinovic; Yesim Parman; Esra Battaloğlu; Zeliha Matur; Velina Guergueltcheva; Ivailo Tournev; Michaela Auer-Grumbach; Peter De Rijk; Britt-Sabina Petersen; Thomas Müller; Erik Fransen; Philip Van Damme; Wolfgang N Löscher; Nina Barišić; Zoran Mitrovic; Stefano C Previtali; Haluk Topaloğlu; Günther Bernert; Ana Beleza-Meireles; Slobodanka Todorovic; Dusanka Savic-Pavicevic; Boryana Ishpekova; Silvia Lechner; Kristien Peeters; Tinne Ooms; Angelika F Hahn; Stephan Züchner; Vincent Timmerman; Patrick Van Dijck; Vedrana Milic Rasic; Andreas R Janecke; Peter De Jonghe; Albena Jordanova
Journal:  Nat Genet       Date:  2012-09-09       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.